Pharmaceuticals & Biotech/Lifesciences

FNArena Windows (Sectors)

Introduction to FNArena Windows

FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.

Latest Stories

Investor focus is firmly on life sciences companies in 2020. FNArena highlights six ASX-listed entities that have been viewed positively by analysts recently

Oct 16 2020

Blood plasma collections have declined globally in the face of the pandemic. Should CSL investors be concerned?

Oct 12 2020


ASX CODE COMPANY NAME LAST PRICE 52WK HIGH 52WK LOW P/E CONSENSUS TARGET
CSL CSL LIMITED $294.43 $342.75 $242.67 40.2

$309.957

EOF ECOFIBRE LIMITED $1.66 $3.90 $1.24 150.9

$2.60

MDC MEDLAB CLINICAL LIMITED $0.18 $0.24 $0.14

$0.32

MYX MAYNE PHARMA GROUP LIMITED $0.31 $0.59 $0.20

$0.368

PAL PALLA PHARMA LTD $0.70 $1.13 $0.45

$1.02

PAR PARADIGM BIOPHARMACEUTICAL $2.80 $xx.xx $xx.xx xx.x xx.xx
PNV POLYNOVO LIMITED $2.74 $xx.xx $xx.xx xx.x xx.xx
SPL STARPHARMA HOLDINGS LIMITED $1.46 $xx.xx $xx.xx xx.x xx.xx
Previous Stories
Spotlight On CSL Revenue Targets

Sep 14 2020

CSL is highly likely to be looking for other avenues of revenue to meet targets in FY21, given a prospective shortfall in plasma collections.


Opportunity in CSL

Sep 08 2020

Michael Gable of Fairmont Equities suggests CSL’s latest drift-back provides an attractive entry point.


Race Oncology Booming Ahead In Times Of Covid

Aug 28 2020

With biotechnology in focus in 2020, Race Oncology is attracting investor interest


ASX Biotechs Surfing The Covid Story

Aug 10 2020

The New Criterion’s Tim Boreham highlights ASX-listed biotechs with skin in the vaccine/treatment game.


Tight Plasma Supply A Benefit For CSL Pricing

Jun 18 2020

CSL may be able to benefit from further price increases as plasma supply is likely to remain tight over the next several months, while brokers welcome the acquisition of Vitaeris.


Hygiene Becomes The New Normal

Jun 01 2020

The New Criterion’s Tim Boreham highlights established environmental hygiene companies benefiting from the virus.


Hand Sanitisers: Clean Up Or Clean Out?

Apr 22 2020

The New Criterion’s Tim Boreham highlights a plethora of listed micro-caps cleaning up on hand sanitiser demand, but might investors get cleaned out?


CSL Plasma Collections Likely To Remain Robust

Mar 24 2020

How exposed is CSL to disruptions to its plasma collections?


All The Dope On Emerald Clinics’ Limp Debut

Feb 21 2020

The New Criterion’s Tim Boreham investigates local opportunities in listed cannabis companies.


A Psychedelic Renaissance

Dec 20 2019

Ahead of the Herd’s Rick Mills explores the development of treatments for various medical conditions using illegal psychedelic drugs. Is LSD the new cannabis?